What to expect
Your time spent as an EEU participant will require several visits to determine eligibility
and prepare you to evaluate the study medication.
After a brief telephone call with a research staff member you may be asked to attend
an information / screening visit when you will be told in detail about the study
and, if you remain interested in participating, you will be asked to provide your
consent to participate. After providing consent, you will undergo several procedures
which may include, but are not limited to:
- a skin prick test
- measurement of vital signs
- brief physical exam
- blood tests and ECGs (electrocardiograms)
If it is determined that you are eligible at the end of the screening visit, you
will be scheduled to attend at least one priming visit at which time you
will be exposed to the pollen and record your allergy symptoms as they occur. The
number of priming visits required is determined by the study protocol and is based
on how long it takes you to reach a pre-determined level of symptoms. If you successfully
complete the priming phase you will be eligible to attend the treatment phase. This
phase can vary in number of days and hours depending on the study protocol. At this
visit you will be asked to record your allergy symptoms as in the priming visits
but will also receive study drug and then continue to record your allergy symptoms
in order to evaluate the onset of action and efficacy of the study drug, as well
as other properties of the study drug.
After you complete the EEU study, an EEU staff member may be required to contact
you to inquire about your health since you participated in the study. An honorarium
may be given at the time you finish participating in the study to compensate for
your time spent and any expenses you have incurred. If you have any questions or
are interested in participating please phone 613-546-5300 / 1-877-6POLLEN or complete
the form below and a member of the EEU recruiting staff will contact you.
